SB82 would override and invalidate certain Kentucky administrative regulations that the General Assembly has found deficient, specifically regulations governing the prescribing, dispensing, or administering of buprenorphine products used to treat opioid use disorder. The bill targets existing and proposed rules in the medical licensure and APRN contexts and declares them null, void, and unenforceable on the act’s effective date. It also bars agencies from adopting substantially similar rules in the future, while keeping the underlying regulations available in the Legislative Research Commission’s regulations compiler.
The bill further adds new statutory provisions directing the Kentucky Board of Medical Licensure, the Kentucky Board of Dentistry, the Kentucky Board of Nursing, and the Kentucky Board of Pharmacy not to promulgate regulations that restrict or limit access to buprenorphine mono-product, buprenorphine/naloxone, or other FDA-approved Schedule III, IV, or V medications for substance use disorder treatment. Each board would still retain authority to regulate controlled substances generally, so long as those rules apply across schedules rather than singling out these medications. The act includes an emergency clause, making it effective immediately upon passage and approval.
The bill’s impact would be to preempt professional licensing boards’ ability to impose medication-specific restrictions on medication-assisted treatment for opioid use disorder, thereby expanding or preserving provider access to these treatments under state law. It would directly affect medical doctors, APRNs, dentists, nurses, pharmacists, and the boards that regulate them, while also limiting the boards’ future rulemaking authority in this area. In practical terms, the bill is designed to reduce regulatory barriers to treatment access for patients with substance use disorder.
The general sentiment reflected by the bill text is strongly supportive of broader access to treatment medications, with the emergency declaration emphasizing the need for prompt access to drugs and medicines for public health and safety. No committee transcript or vote history was provided, so there is no recorded debate or roll-call evidence here to indicate opposition or amendment activity. Based on the text alone, the bill appears framed as a public-health access measure rather than a punitive or restrictive one.
The main point of contention likely concerns the balance between access to medication-assisted treatment and the authority of professional licensing boards to set prescribing standards. The bill expressly removes board discretion to impose medication-specific limits, which could be viewed by supporters as necessary to prevent unnecessary barriers, but by critics as an intrusion on professional regulation and patient-safety oversight. Another possible issue is the breadth of the preemption language, which reaches not only current rules but also future regulations that are identical or substantially similar.
SB82 would amend Kentucky law by creating new statutory prohibitions on state licensing boards’ ability to regulate buprenorphine and other FDA-approved substance use disorder medications in a restrictive, medication-specific way. It would invalidate identified administrative regulations in KRS Chapter 13A and bar agencies from reenacting substantially similar rules, while preserving general controlled-substance regulation authority. The bill would affect the Kentucky Board of Medical Licensure, Board of Dentistry, Board of Nursing, and Board of Pharmacy, as well as prescribers and patients receiving medication-assisted treatment.
The bill’s stated purpose and emergency clause suggest a pro-access, public-health-oriented approach focused on expanding timely treatment for substance use disorder. Because no committee discussion or votes were provided, there is no direct evidence of opposition or support from legislators in the record supplied. On its face, the measure appears designed to reduce regulatory barriers and is presented in a favorable light toward treatment access.
The likely controversy is whether the General Assembly should override professional boards’ authority to set prescribing and dispensing standards for buprenorphine and related medications. Supporters would likely argue that the bill prevents unnecessary restrictions and improves access to opioid use disorder treatment, while opponents may argue that it limits boards’ ability to protect patient safety and maintain professional standards. The bill’s broad preemption of future similar regulations may also be a point of concern for regulators who want flexibility to respond to changing clinical or public-safety conditions.